| | | 100 × CD4+CD25+/CD4+ (N) |
---|
Treatment | Expt no. | Organ | IFN-γR KO | WT |
---|
Naive | 1 | Thymus | 3.2 ± 0.6 (5) | 2.2 ± 0.7 (5) |
| | Spleen | 10.1 ± 0.9 (3) * | 7.4 ± 0.2 (3) |
| | Lymph nodes | 6.9 ± 1.1 (5) | 5.1 ± 1.1 (5) |
| 2 | Spleen | 14.4 (1) | 9.9 (1) |
| | Lymph nodes | 9.1 ± 0.9 (4) | 6.6 ± 0.7 (4) |
| 3 | Lymph nodes | 11.2 (1) | 7.0 (1) |
CIA | 4 | Thymus | 3.5 ± 0.9 (3) | 4.0 ± 1.6 (3) |
| | Spleen | 11.0 ± 1.3 (2) | 7.9 ± 0.7 (2) |
| | Lymph nodes | 10.2 ± 0.8 (6) | 7.7 ± 0.6 (6) |
| 5 | Spleen | 12.1 ± 2.9 (3) | 9.2 ± 0.8 (3) |
| | Lymph nodes | 12.9 ± 1.4 (4) | 10.3 ± 1.1 (4) |
| 6 | Lymph nodes | 13.4 ± 0.4 (4) * | 9.2 ± 0.7 (4) |
- Cells were obtained from thymuses, spleens or lymph nodes of IFN-γ receptor knock-out (IFN-γR KO) and wild-type DBA/1 mice. In experiments 4 to 6, mice were immunised with collagen type II in complete Freund's adjuvant on day 0, and cells were obtained on day 21 (collagen-induced arthritis; CIA). Cells were stained with anti-CD25-FITC and phycoerythrin-conjugated anti-CD4 antibodies. The proportion of CD4+CD25+ in the total CD4+ T cell population is shown. In experiments 1, 2, 4 and 5, N (number in parentheses) indicates the number of mice in each experiment; in experiments 3 and 6, N represents the number of experiments, each consisting of groups of 5 to 10 mice, from which samples were pooled for analysis. *Significant difference between IFN-γR KO and wild-type mice (P < 0.05; Mann–Whitney U-test).